David Luterman, MD
Pulmonary Disease · Dallas, TXNPI 1629079751
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 582 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,039 and has fallen 55.0% since, to $1,369 in 2025.
Across 582 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$2K
- Mylan Specialty L.p.$845
- Insmed, Inc.$739
- Resmed Corp$556
- plus $5K from 43 others
What the payments were for
- Consulting fees$580%
- Food & beverage$11,71994%
- Education$2372%
- Gifts$4804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AirSense$480
- remede System$144
- OFEV$123
- FASENRA$108
How this compares
$12,494 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 40 | $558,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 311 | $324,878 |
| Breo ElliptaFluticasone/Vilanterol | 136 | $96,654 |
| XolairOmalizumab | 13 | $69,553 |
| Dupixent SyringeDupilumab | 14 | $52,389 |
| Dupixent PenDupilumab | 13 | $52,180 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $51,126 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $35,851 |
| BelsomraSuvorexant | 24 | $16,189 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,603 |
| Spiriva HandihalerTiotropium Bromide | 13 | $13,777 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $11,733 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $10,410 |
| Arnuity ElliptaFluticasone Furoate | 20 | $7,705 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $7,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,545 | $583,21965 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,634 | $465,088524 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,271 | $67,31178 claims |
| MerckBelsomra, Dulera | $33 | $21,72937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.